New gene therapy for ALS enters first human safety trial
NCT ID NCT07401121
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage study tests a single dose of a gene therapy called CTx1000 in 15 people with ALS. The main goal is to see if it is safe and tolerable. Participants must have had ALS for 2 years or less and be on stable standard medications. This is not a cure; it aims to control the disease.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALS - AMYOTROPHIC LATERAL SCLEROSIS are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Macquarie University Hospital
RECRUITINGSydney, New South Wales, 2109, Australia
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Blood markers may unlock early ALS detection — a study puts them to the test
- Brain implant aims to give voice to those trapped in silence
- Nasal spray aims to tame brain inflammation in ALS
- Robotic arm could help people with paralysis regain independence at home
- Experimental cell therapy tested in 3 ALS patients
- Gene therapy injection hopes to slow ALS